Shusuke Yagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shusuke Yagi has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Takashi Iwase
Department of Cardiovascular Medicine, Tokushima University Hospital
16 shared publications- Hirotsugu Yamada
Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
14 shared publications - Kenya Kusunose
Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus, Okinawa, Japan
12 shared publications Koji Yamaguchi
11 shared publications- Masataka Sata
Department of Cardiovascular Medicine, Tokushima University Hospital
10 shared publications Masashi Akaike
Department of Medical Education, The University of Tokushima Graduate School of Health Biosciences, Tokushima, Japan
9 shared publications
Latest Publications
- 1 January 2017
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 81 (2) , 271
Nocardia Identification at the Genus Level - Reply.
- 1 January 2017
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 81 (2) , 271
Nocardia Identification at the Genus Level - Reply.
- 1 October 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (10) , S185
Successful Surgical Repair of Aged Sinus Venosus Atrial Septal Defect with Partial Anomalous Pulmonary Venous Connection: A Case Report
- 1 October 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (10) , S185
Successful Surgical Repair of Aged Sinus Venosus Atrial Septal Defect with Partial Anomalous Pulmonary Venous Connection: A Case Report
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 104 (6) , 1175-1179
Successful Treatment with Methotrexate and Low-dose Corticosteroids for Recurrent Cardiac Sarcoidosis
心臓サルコイドーシスの標準的治療はステロイドであるが,ステロイドを投与中であっても再燃を認めることも多く,またステロイドの多岐にわたる副作用も問題となることが多い.症例は70歳代,女性.心臓サルコイドーシスの診断でプレドニンを維持量5 mg/日で加療されていた.定期検査で施行した心電図で陰性T波,前壁心尖部に新規の左室壁運動異常を認めた.FDG-PET,Gaシンチグラフィーで壁運動異常部位に一致して集積を認め,心臓サルコイドーシスの再燃と判断した.本症例では,ステロイドの副作用として糖尿病,肥満,白内障などを認めており,ステロイド増量が躊躇され,メトトレキサートの併用を開始した.メトトレキサート開始後,特に副作用を認めず,心電図ならびに左室壁運動異常の改善が認められた.ステロイド投与で再燃を認める心臓サルコイドーシス症例にはメトトレキサート併用も考慮すべきであると考えられた.
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 104 (6) , 1175-1179
Successful Treatment with Methotrexate and Low-dose Corticosteroids for Recurrent Cardiac Sarcoidosis
心臓サルコイドーシスの標準的治療はステロイドであるが,ステロイドを投与中であっても再燃を認めることも多く,またステロイドの多岐にわたる副作用も問題となることが多い.症例は70歳代,女性.心臓サルコイドーシスの診断でプレドニンを維持量5 mg/日で加療されていた.定期検査で施行した心電図で陰性T波,前壁心尖部に新規の左室壁運動異常を認めた.FDG-PET,Gaシンチグラフィーで壁運動異常部位に一致して集積を認め,心臓サルコイドーシスの再燃と判断した.本症例では,ステロイドの副作用として糖尿病,肥満,白内障などを認めており,ステロイド増量が躊躇され,メトトレキサートの併用を開始した.メトトレキサート開始後,特に副作用を認めず,心電図ならびに左室壁運動異常の改善が認められた.ステロイド投与で再燃を認める心臓サルコイドーシス症例にはメトトレキサート併用も考慮すべきであると考えられた.
- 1 August 2014
- Vol. 72 (8) , 1466-71
[Renin-angiotensin-aldosterone inhibitors for treatment of hypertension with abnormal circadian rhythm of blood pressure].
Circadian rhythm of blood pressure (BP) has recently been focused on because increase in nocturnal BP and morning BP surge have been shown to be risks for cardio-cerebrovascular diseases independent of 24-h BP level. The renin-angiotensin-aldosterone system (RAAS) is involved in BP circadian rhythm, and RAAS inhibitors therefore play an important role in the control of circadian rhythm of BP. Bedtime administration of RAAS inhibitors is more effective than morning administration for reducing nocturnal and morning BP levels in addition to converting the BP profile into a dipper pattern, which is known as chronotherapy. For reducing cardio-cerebro-vascular events, controlling abnormal circadian rhythm of BP in addition to 24-h BP using RAAS inhibitors with optimal time dosing should be considered.
- 1 August 2014
- Vol. 72 (8) , 1466-71
[Renin-angiotensin-aldosterone inhibitors for treatment of hypertension with abnormal circadian rhythm of blood pressure].
Circadian rhythm of blood pressure (BP) has recently been focused on because increase in nocturnal BP and morning BP surge have been shown to be risks for cardio-cerebrovascular diseases independent of 24-h BP level. The renin-angiotensin-aldosterone system (RAAS) is involved in BP circadian rhythm, and RAAS inhibitors therefore play an important role in the control of circadian rhythm of BP. Bedtime administration of RAAS inhibitors is more effective than morning administration for reducing nocturnal and morning BP levels in addition to converting the BP profile into a dipper pattern, which is known as chronotherapy. For reducing cardio-cerebro-vascular events, controlling abnormal circadian rhythm of BP in addition to 24-h BP using RAAS inhibitors with optimal time dosing should be considered.
- 1 October 2013
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 19 (10) , S172
Progression of a Case of Myocardial Damage Caused by Becker’s Muscular Dystrophy
- 1 October 2013
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 19 (10) , S172
Progression of a Case of Myocardial Damage Caused by Becker’s Muscular Dystrophy
- 23 May 2013
- Published by Springer Nature in Hypertension Research
- Vol. 36 (9) , 753-758
Renin–angiotensin–aldosterone system has a pivotal role in cognitive impairment
Because dementia is associated with both deterioration in the quality of life and poor prognosis, the prevention of cognitive impairment (CI) is a critical problem in public health promotion. Hypertension is a risk factor for the aggravation of CI, and the renin–angiotensin–aldosterone system (RAAS) is a key player in the increased incidence and development of hypertension. Therefore, the RAAS is considered to be a promoting factor for CI development. Conversely, recent studies have shown that lowering blood pressure with RAAS inhibitors decreases the incidence of CI, dementia and cardiovascular disease. Blood–brain barrier-penetrating RAAS inhibitors appear to have advantages in preventing cognitive decline because they can suppress the RAAS in the hippocampus, which has an important role in cognition. Thus, RAAS blockage is a notable strategy for preventing CI.
- 23 May 2013
- Published by Springer Nature in Hypertension Research
- Vol. 36 (9) , 753-758
Renin–angiotensin–aldosterone system has a pivotal role in cognitive impairment
Because dementia is associated with both deterioration in the quality of life and poor prognosis, the prevention of cognitive impairment (CI) is a critical problem in public health promotion. Hypertension is a risk factor for the aggravation of CI, and the renin–angiotensin–aldosterone system (RAAS) is a key player in the increased incidence and development of hypertension. Therefore, the RAAS is considered to be a promoting factor for CI development. Conversely, recent studies have shown that lowering blood pressure with RAAS inhibitors decreases the incidence of CI, dementia and cardiovascular disease. Blood–brain barrier-penetrating RAAS inhibitors appear to have advantages in preventing cognitive decline because they can suppress the RAAS in the hippocampus, which has an important role in cognition. Thus, RAAS blockage is a notable strategy for preventing CI.
- 1 May 2013
- Vol. 29 (3) , 201-7
Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems.
It is well-known that aldosterone plays an important role in reabsorption of sodium and fluid, and in potassium excretion in kidneys via epithelial mineralocorticoid receptor (MR) activation. Recent studies have shown that aldosterone causes cardiovascular remodeling not only in a blood pressure-dependent manner, but also in a blood pressure-independent manner by decreasing nitric oxide bioavailability and modulating oxidative stress, leading to vascular inflammation. In addition, MR blockade does provide beneficial effects associated with cardiovascular protection, resulting in a reduction of cardiovascular morbidity and mortality. A growing body of evidence suggests that MR blockade is a promising therapeutic target to help prevent cardiovascular events. Aldosterone; Mineralocorticoid receptor; Nitrix oxide; Renin-angiotensin-aldosterone system.
- 1 May 2013
- Vol. 29 (3) , 201-7
Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems.
It is well-known that aldosterone plays an important role in reabsorption of sodium and fluid, and in potassium excretion in kidneys via epithelial mineralocorticoid receptor (MR) activation. Recent studies have shown that aldosterone causes cardiovascular remodeling not only in a blood pressure-dependent manner, but also in a blood pressure-independent manner by decreasing nitric oxide bioavailability and modulating oxidative stress, leading to vascular inflammation. In addition, MR blockade does provide beneficial effects associated with cardiovascular protection, resulting in a reduction of cardiovascular morbidity and mortality. A growing body of evidence suggests that MR blockade is a promising therapeutic target to help prevent cardiovascular events. Aldosterone; Mineralocorticoid receptor; Nitrix oxide; Renin-angiotensin-aldosterone system.
- Open Access
- 10 September 2012
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 11 (1) , 106
Gender disparities in the association between epicardial adipose tissue volume and coronary atherosclerosis: A 3-dimensional cardiac computed tomography imaging study in Japanese subjects
Background: Growing evidence suggests that epicardial adipose tissue (EAT) may contribute to the development of coronary artery disease (CAD). In this study, we explored gender disparities in EAT volume (EATV) and its impact on coronary atherosclerosis. Methods: The study population consisted of 90 consecutive subjects (age: 63 ± 12 years; men: 47, women: 43) who underwent 256-slice multi-detector computed tomography (MDCT) coronary angiography. EATV was measured as the sum of cross-sectional epicardial fat area on CT images, from the lower surface of the left pulmonary artery origin to the apex. Subjects were segregated into the CAD group (coronary luminal narrowing > 50%) and non-CAD group. Results: EATV/body surface area (BSA) was higher among men in the CAD group than in the non-CAD group (62 ± 13 vs. 33 ± 10 cm3/m2, p < 0.0001), but did not differ significantly among women in the 2 groups (49 ± 18 vs. 42 ± 9 cm3/m2, not significant). Multivariate logistic analysis showed that EATV/BSA was the single predictor for >50% coronary luminal narrowing in men (p < 0.0001). Predictors excluded were age, body mass index, hypertension, diabetes mellitus, and hyperlipidemia. Conclusions: Increased EATV is strongly associated with coronary atherosclerosis in men.
- 10 September 2012
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 11 (1) , 106
Open AccessGender disparities in the association between epicardial adipose tissue volume and coronary atherosclerosis: A 3-dimensional cardiac computed tomography imaging study in Japanese subjects
Background: Growing evidence suggests that epicardial adipose tissue (EAT) may contribute to the development of coronary artery disease (CAD). In this study, we explored gender disparities in EAT volume (EATV) and its impact on coronary atherosclerosis. Methods: The study population consisted of 90 consecutive subjects (age: 63 ± 12 years; men: 47, women: 43) who underwent 256-slice multi-detector computed tomography (MDCT) coronary angiography. EATV was measured as the sum of cross-sectional epicardial fat area on CT images, from the lower surface of the left pulmonary artery origin to the apex. Subjects were segregated into the CAD group (coronary luminal narrowing > 50%) and non-CAD group. Results: EATV/body surface area (BSA) was higher among men in the CAD group than in the non-CAD group (62 ± 13 vs. 33 ± 10 cm3/m2, p < 0.0001), but did not differ significantly among women in the 2 groups (49 ± 18 vs. 42 ± 9 cm3/m2, not significant). Multivariate logistic analysis showed that EATV/BSA was the single predictor for >50% coronary luminal narrowing in men (p < 0.0001). Predictors excluded were age, body mass index, hypertension, diabetes mellitus, and hyperlipidemia. Conclusions: Increased EATV is strongly associated with coronary atherosclerosis in men.
- 15 December 2011
- Published by Elsevier in International Journal of Cardiology
- Vol. 153 (3) , 272-276
Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina
- 15 December 2011
- Published by Elsevier in International Journal of Cardiology
- Vol. 153 (3) , 272-276
Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina